incretin glp 1 hormones and the satiation signal GLP-1 Agonists: Increasing Effective Insulin

[Zepbound] is a power tool, and patients need to consider what they are willing to change in their lifestyle because if protein requirements and strength training are not in place, people can lose muscle and be predisposed to regaining fat mass if they stop the medicine, she said

Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms

However, its benefit is mainly dependent on adherence, which remains suboptimal in many patients due to discomfort and inconvenience, with adherence rates often falling below 50% in routine clinical practice [22]

Supporting healthy GLP-1 Levels isn't just about medication lifestyle factors play a role too

While you can get a general idea of what to eat by doing research, remember to always speak to your physician to find what is the best semaglutide diet plan for you and your needs